HMPL-013 clinical trials
Also written Fruquintinib, HMPL-013 and Fruzaqla.
How each study uses HMPL-013 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HMPL-013 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 8 Nov 2023 · FRUZAQLA · NDA 217564 (FDA, Drugs@FDA)
- European Union
- 20 Jun 2024 · Fruzaqla · EMEA/H/C/005979 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
120 studies that test it; most in 2022 (22)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 13 |
| 2022 | 22 |
| 2023 | 21 |
| 2024 | 9 |
| 2025 | 19 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 94
Hutchison Medipharma Limited (15) · Fudan University (14) · Sun Yat-sen University (9) · Hutchmed (7) · Wuhan Union Hospital, China (3) · Federation Francophone de Cancerologie Digestive (3) · RenJi Hospital (2) · Henan Cancer Hospital (2)
Often tested with
Tested in the same studies.
Tislelizumab (15) · Sintilimab (14) · Capecitabine (7) · Serplulimab (6) · FOLFIRI-Ziv-aflibercept Regimen (5) · FOLFIRI Regimen (5) · Disitamab vedotin (3) · Camrelizumab (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
HMPL-013 is the comparator. A study of two new drugs counts under both.
- 1Tucidinostat · Chipscreen Biosciences, Ltd. · next primary completion May 2028
- 1Sintilimab · Chipscreen Biosciences, Ltd. · next primary completion May 2028
Reaching primary completion within a year · 16
Studies that test HMPL-013.
- Dec 2026A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above TreatmentPhase 2 · Harbin Medical University
- Dec 2026A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyPhase 2 · Fudan University
- Dec 2026Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical TrialPhase 2 · Jing-yuan Fang, MD, Ph. D
- Dec 2026SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRCPhase 2 · Wuhan Union Hospital, China
- Jan 2027A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)Phase 2 · SCRI Development Innovations, LLC
- Jan 2027FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal CancerPhase 4 · Ye Xu
- Mar 2027Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)Phase 2 · Korea University Anam Hospital
- May 2027Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ AdenocarcinomaPhase 2 · Sichuan University
- Jun 2027Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian CancerPhase 2 · Fudan University
- Jul 2027A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal CancerPhase 1/2 · National Cancer Center Hospital East
Studies
Open first, then newest update. How each study uses HMPL-013 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 120
- A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell CarcinomaNot yet recruitingPhase 3Sun Yat-sen UniversityNCT07904156Written as Serplulimab + Fruquintinib
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNot applicableHarbin Medical UniversityNCT07552402Written as Oral Paclitaxel Solution Plus Fruquintinib
- Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later TreatmentRecruitingPhase 2Renmin Hospital of Wuhan UniversityNCT07896096Written as Fruquintinib
- SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal CancerRecruitingPhase 2Ruijin HospitalNCT07888309Written as Fruquintinib
- Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal CancerNot yet recruitingPhase 3West China HospitalNCT07885384Written as Fruquintinib Combined With Capecitabine
- A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric CancerNot yet recruitingPhase 2Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterNCT07819019Written as Fruquintinib
- Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT06484153Written as Fruquintinib
- Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRCRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07724223Written as Fruquintinib plus Cetuximab-beta
- A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal CancerRecruitingPhase 4TakedaNCT06562543Written as Fruquintinib
- Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ AdenocarcinomaNot yet recruitingPhase 2Sichuan UniversityNCT07658872Written as fruquintinib + sintilimab + SOX
- A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)RecruitingPhase 2SCRI Development Innovations, LLCNCT07011576Written as fruquintinib
- A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal CanceNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07622550Written as Serplulimab+Fruquintinib+XELOX
- Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal CancerRecruitingNot applicableFederation Francophone de Cancerologie DigestiveNCT07124858Written as Fruquintinib
- A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal CancerNot yet recruitingPhase 1/2National Cancer Center Hospital EastNCT07591597Written as Fruquintinib
- Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal CancerRecruitingPhase 2The Methodist Hospital Research InstituteNCT07042685Written as Fruquintinib Combined With Chemotherapy
- Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)Not yet recruitingPhase 2Korea University Anam HospitalNCT07510932Written as Fruquintinib
- FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal CancerNot yet recruitingPhase 4Ye XuNCT07446465Written as Fruquintinib
- Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric AdenocarcinomaRecruitingPhase 3Federation Francophone de Cancerologie DigestiveNCT07270991Written as fruquintinib
- Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)Not yet recruitingPhase 3Fudan UniversityNCT07362836Written as fruquintinib+chemotherapy
- A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyRecruitingPhase 2Fudan UniversityNCT05954429Written as Fruquintinib
See all 120 studies that test HMPL-013 →
Given beside what is tested · 29 — HMPL-013 is usual care or a partner of the new treatment
- ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsRecruitingPhase 1/2Adagene IncNCT05405595Written as Standard of care (Fruquintinib)
- A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal CarcinomaRecruitingPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT07791758Written as Fruquintinib Capsules
- A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanNot yet recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07730489Written as Fruquintinib
- Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07689292Written as Sacituzumab Tirumotecan + Fruquintinib
- A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal CancerNot yet recruitingPhase 1/2Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07621159Written as Fruquintinib
- SHR-3821 in Advanced Colorectal Cancer: an Exploratory StudyNot yet recruitingPhase 2Meng QiuNCT07515820Written as SHR-3821 and fruquintinib
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal CancerNot yet recruitingPhase 2Huazhong University of Science and TechnologyNCT07502014Written as Fruquintinib
- Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric CancerRecruitingPhase 2Dai, GuanghaiNCT07392346Written as Fruquintinib
- A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.RecruitingPhase 1/2AskGene Pharma, Inc.NCT05867420Written as Fruquintinib
- Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal CancerRecruitingPhase 2/3Sun Yat-sen UniversityNCT06441565Written as Fruquintinib
- Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ CancerRecruitingPhase 1/2Henan Cancer HospitalNCT06329973Written as Fruquintinib in combination with Sintilimab and CAPEOX
- An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.Not yet recruitingNot applicableLiu HuangNCT06985316Written as Tunlametinib combined with Fruquintinib
- A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal CancerRecruitingPhase 2The First Hospital of Jilin UniversityNCT06979908Written as Fruquintinib+Sintilimab+Chidamide
- Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal CancerRecruitingPhase 1/2Liu HuangNCT06980532Written as Glumetinib Combined with Fruquintinib
- Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic ProgressionNot yet recruitingPhase 2/3Queling LiuNCT06977061Written as Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy
- Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric CancerRecruitingPhase 2First Affiliated Hospital of Fujian Medical UniversityNCT06791083Written as Fruquintinib
- Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal CancerRecruitingPhase 2Dai, GuanghaiNCT06685276Written as Fruquintinib
- Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRCRecruitingNot applicableLiu HuangNCT06551207Written as Fruquintinib
- ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal CancerRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06543836Written as Fruquintinib
- Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal CancerNot yet recruitingPhase 2Fudan UniversityNCT06423937Written as combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab
Showing 20 of 29.
As the comparator · 4 — what is tested is compared with HMPL-013
- GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal CancerNot yet recruitingPhase 3Genfleet Therapeutics (Shanghai) Inc.NCT07913360Written as Fruquintinib
- A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal CancerRecruitingPhase 2Criterium, Inc.NCT06992258Written as Fruquintinib
- A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.RecruitingPhase 2Kahr Bio Australia Pty LtdNCT07235293Written as Fruquintinib
- A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer PatientsRecruitingPhase 3Chipscreen Biosciences, Ltd.NCT06497985Written as Fruquintinib
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered4
- A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell CarcinomaOct 29, 2026NCT07904156
- Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later TreatmentOct 26, 2026NCT07896096
- SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal CancerOct 22, 2026NCT07888309
- Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal CancerOct 21, 2026NCT07885384
Codes
What other systems call HMPL-013 · ClinicalTrials.gg INT000075
- MeSH (NLM) C000591844HMPL-013Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 49DXG3M5ZWFRUQUINTINIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000591844 | HMPL-013 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 49DXG3M5ZW | FRUQUINTINIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.